Oramed Pharmaceuticals adopts amended bylaws with new stockholder consent rules and indemnification limits

ORAMED PHARMACEUTICALS INC.

Board adopted Fourth Amended and Restated By-laws effective February 23, 2023.
New rules for stockholder action by written consent, including record date and independent inspector of election.
Limits indemnification for proceedings commenced by the person unless board-authorized.
Reduces indemnification by amounts collected from other entity for service at another entity.
Requires affirmative vote of majority of outstanding shares to alter, amend, or repeal bylaws.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ORAMED PHARMACEUTICALS INC.: Adopted Fourth Amended and Restated By-laws implementing rules for stockholder action by written consent, eliminating outdated provisions, limiting indemnification, and requiring majority vote for amendments (effective 2023-02-23).

Change: bylaw amendment
Effective: 2023-02-23

Exact text from the filing

On February 23, 2023, the board of directors of Oramed Pharmaceuticals Inc. (the “Company”) adopted Fourth Amended and Restated By-laws (the “By-laws”), which became effective immediately

View on SEC.gov

Browse all governance changes →

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-014884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.